Avila Therapeutics appoints chief executive
Avila Therapeutics, a Waltham biopharmaceutical company, said that Katrine S. Bosley has been appointed as chief executive.
Bosley joins Avila from Adnexus, where she served as vice president of business development and later as vice president of strategic operations, establishing an alliance with and subsequent acquisition by Bristol-Myers Squibb, Avila Therapeutics said.
Avila Therapeutics is developing a new therapeutic approach called 'protein silencing' based on a proprietary platform for developing covalent drugs that strongly and resiliently bond to disease-causing proteins.
To read the company's press release, please click here.
(By Chris Reidy, Globe staff)